Novonesis A/s Class B · OMXCOP:NSIS_B

Novonesis A/s Class B — Novozymes — 9M 2013 Earnings Presentation

8 slides from Novonesis A/s Class B's earnings presentation, Oct 25, 2013

  1. Slide 1: Conference Call 9M 2013

    CONFERENCE CALL 9M 2013 October 25, 2013

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation and its related comments contain forward-looking statements, including financial expectations. Forward-looking statements are by their very nature associated with risks and uncertainties that may cause actual results to differ materially from expectations. The

  3. Slide 3: 9M 2013 Summary

    9M 2013 Summary 9M performance in line with expectations Accumulated organic sales growth and guidance, 2012 & 2013 • 6% organic sales growth after 9M (7% in Q3) 8% driven by all industries, spearheaded by Household 6% 2013 Care 4% 2012 • Significant headwind from currencies 2% 0% • EBIT margin up b

  4. Slide 4: Sales & Markets

    Sales & Markets First 9M sales in line with expectations Sales by industry, DKKm  9M 2013 sales: DKK +5%, LCY +7%, org: +6% 9M 2013 9M 2012  Q3 2013 sales: DKK +3%, LCY +8%, org: +7% Household 3,156 +5%/+8% Care 2,997 Q3: +8% • Household Care continued on growth track, as strong performance in eme

  5. Slide 5: In Detail: Corn Ethanol Customers Adopt New Enzyme Technology

    In Detail: Corn Ethanol Customers Adopt New Enzyme Technology New technology has been well received by Quarterly growth rates, 2012-2013 customers and we are outperforming the 30% market: US ethanol production 20% Bioenergy organic sales growth • Avantec® has now been one year in the 10% market plac

  6. Slide 6: Innovation - New Evity Platform for Household Care

    Innovation - New Evity® Platform for Household Care The Evity® Platform: Improved Granulate Illustration • New stability technology for High-strength Household Care aiming at taking enzyme-containing core with stabilizing stability to next level technology • Relevant for both granulate and liquid fo

  7. Slide 7: 9M 2013 Financial Performance & FY 2013 Outlook

    9M 2013 Financial Performance & FY 2013 Outlook Satisfactory earnings development in dynamic Realized Outlook Outlook currency environment Key financials 9M 2013 October 25 August 9 • Increase of both gross and EBIT Sales growth, +5% 3-5% 5-7% margin despite currency headwinds DKK and higher cost ba

  8. Slide 8: Novozymes - Rethink Tomorrow

    novozymes’ Rethink Tomorrow

Novozymes — 9M 2013 Earnings Presentation on 6ix